(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 October 2015 (15.10.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/155141 A1

(51) International Patent Classification:
C07K 14/435 (2006.01)

(21) International Application Number:
PCT/EP2015/057418

(22) International Filing Date:
2 April 2015 (02.04.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
14305503.6 7 April 2014 (07.04.2014) EP

(71) Applicant: **SANOFI** [FR/FR]; 54 rue La Boétie, F-75008 Paris (FR).

(72) Inventors: **BOSSART, Martin**; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **ELVERT, Ralf**; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **EVERS, Andreas**; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **HAACK, Torsten**; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **STENGELIN, Siegfried**; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **WAGNER, Michael**; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **LORENZ, Katrin**; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE).

(74) Agents: **WEISS, Wolfgang** et al.; Weickmann & Weickmann, Richard-Strauss-Strasse 80, 81679 München (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2015/155141 A1

(54) Title: PEPTIDIC DUAL GLP-1 / GLUCAGON RECEPTOR AGONISTS DERIVED FROM EXENDIN-4

(57) Abstract: Peptidic dual GLP-1 / Glucagon Receptor Agonists derived from Exendin-4 The present invention relates to dual GLP-1 / glucagon receptor agonists or optionally trigonal GLP-1 / glucagon / GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.